Tumor Models Archives - Page 3 of 11

Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...

Developing Resistant Models to Diverse ADC Drugs

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

Targeting FAK Improves the Tumor Uptake of ADCs

Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...

BRCA2 Deficient DLD-1 Model

BRCA1 and BRCA2 proteins are key components of the homologous recombination repair pathway for repairing double-stranded DNA breaks. Mutations in...

PRMT5 Related Tumor Models

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. MTAP deletions occur in...

Developing Novel AR Mutant Prostate Cancer Models

Since prostate cancer heavily depends on androgen hormones for growth, targeting the androgen receptor (AR) signaling pathway is a key...

BTK Inhibitor-Resistant Lymphoma Animal Models

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use...

Oncogenic Virus-associated Tumor Models

Viruses have well-established causal roles in numerous human cancers. Approximately 10% of cancers globally are attributed to viral infections, primarily...

OncoWuXi Express: Comprehensive PDX Panel Service for Drug Discovery

OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well...

Knowledge Library